AI assistant
ACHIEVE LIFE SCIENCES, INC. — Director's Dealing 2013
Feb 6, 2013
33882_dirs_2013-02-06_d0d29c50-613e-476f-80e4-5dee765c4b6b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: ONCOGENEX PHARMACEUTICALS, INC. (OGXI)
CIK: 0000949858
Period of Report: 2013-02-01
Reporting Person: Wyrick Susan D. (PAO)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $13.44 | 2022-06-29 | Common Stock (5500) | Direct | |
| Restricted Stock Units | $ | 2016-07-29 | Common Stock (2750) | Direct | |
| Restricted Stock Units | $ | 2014-04-30 | Common Stock (2573) | Direct |
Footnotes
F1: The stock options vest monthly over 4 years commencing one month from June 29, 2012, with 100% vested on June 29, 2016.
F2: The restricted stock units vest 25% annually on the later of (i) each anniversary of June 29, 2012; and (ii) the first day thereafter during which the issuer's trading window is open.
F3: Each restricted stock unit represents a contingent right to receive one share of the issuer's Common Stock.
F4: The restricted stock units vest 100% on the later of (i) achievement of both the successful enrollment and release of data from certain clinical trials, and (ii) the first trading day thereafter on which the issuer's trading window is open.